Clinical Trial Update: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes the AZA-AEGEAN regimen—neoadjuvant inhaled azacitidine with platinum-based chemotherapy and durvalumab—for operable early-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Azacitidine (inhaled) (azacitidine)
• Durvalumab (durvalumab)
• Platinum-based chemotherapy regimen

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1, Phase 2 | Status: RECRUITING